Radioactive drug plus immunotherapy shows promise for rare skin cancer
NCT ID NCT05583708
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and lutetium Lu 177 dotatate (a radioactive drug that kills cancer cells)—in 18 adults with Merkel cell carcinoma. The goal is to see if the combination can shrink or control tumors. Both drugs are FDA-approved for other cancers, but their use together for Merkel cell cancer is experimental.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Iowa Hospitals and Clinics
RECRUITINGIowa City, Iowa, 52242, United States
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Email: •••••@•••••
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Blood markers could spot hidden skin cancer return
- Cancer-Killing virus shows promise in early trial for advanced tumors
- Immune cell therapy shows promise for tough cancers
- New database aims to crack the code on three rare skin cancers
- New scan could spot hidden tumors more accurately